the negatives were cleary specified. In his opinion it is too risky and too expensive.wouldn't mind comparing notes coz my assessment has it undervalued with minimal risk.just have to wait a bit to see who is correct.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%